The high proportion of byproducts and low yield are explained by the easily reversible nature of the aldol condensation, and carbonyl chemistry in general.
The dyspnea risks following cangrelor treatment, suggest a common mechanism linking transfusion-related acute lung injury, dyspnea, and reversible platelet inhibition.
